Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.69
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell